



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/724,292	12/01/2003	Juan Armendariz Borunda	5585-036-999	4513
9629	7590	01/28/2008	EXAMINER	
MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004			CHEN, SHIN LIN	
		ART UNIT	PAPER NUMBER	
		1632		
		MAIL DATE	DELIVERY MODE	
		01/28/2008	PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	10/724,292	ARMENDARIZ BORUNDA ET AL.
	Examiner Shin-Lin Chen	Art Unit 1632

— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) Responsive to communication(s) filed on 31 October 2007.
- 2a) This action is **FINAL**.                                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) Claim(s) 22,24-30 and 32-34 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 22, 24-30 and 32-34 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
  1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.	6) <input type="checkbox"/> Other: _____

## DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10-31-07 has been entered.

Applicants' amendment filed 10-31-07 has been entered. Claims 22, 24 and 32 have been amended. Claims 33 and 34 have been added. Claims 22, 24-30 and 32-34 are pending and under consideration.

2. The claims are generally narrative and indefinite, failing to conform with current U.S. practice. They appear to be a literal translation into English from a foreign document and are replete with grammatical and idiomatic errors.

### *Claim Rejections - 35 USC § 112*

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 22, 24-30 and 32-34 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for reducing fibrosis in hepatic cirrhosis by injecting via iliac vein a replication defective adenovirus vector AdMMP-8 expressing human MMP-8 protein under the control of CMV promoter as disclosed in the cited references Siller-Lopez et al., 2004 (Gastroenterology, Vol. 126, p. 1122-1133) and Garcia-Banuelos et al., 2002 (Gene Therapy,

Vol. 9, p. 127-134) (amendment filed on 10-31-07), does not reasonably provide enablement for a pharmaceutical composition comprising recombinant adenovirus expressing the proteins as recited in the claims under the control of various promoters, and a method for treating various fibrotic disorders by using said pharmaceutical composition via various administration routes or administration to various organs. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

While determining whether a specification is enabling, one considered whether the claimed invention provides sufficient guidance to make and use the claimed invention, if not, whether an artisan would have required undue experimentation to make and use the claimed invention and whether working examples have been provided. When determining whether a specification meets the enablement requirement, some of the factors that need to be analyzed are: the breadth of the claims, the nature of the invention, the state of the prior art, the level of one of ordinary skill, the level of predictability in the art, the amount of direction provided by the inventor, the existence of working examples, and whether the quantity of any necessary experimentation to make or use the invention based on the content of the disclosure is "undue" (In re Wands, 858 F.2d at 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)).

Furthermore, the USPTO does not have laboratory facilities to test if an invention with function as claimed when working examples are not disclosed in the specification, therefore, enablement issues are raised and discussed based on the state of knowledge pertinent to an art at the time of the invention, therefore skepticism raised in the enablement rejections are those raised in the art by artisans of expertise.

Claims 22, 24-30 and 32-34 are directed to a pharmaceutical composition comprising a therapeutically effective amount of unitary doses of viral particles of recombinant adenoviral vectors containing a therapeutic gene or DNA sequence under the control of a ubiquitous promoter, a tissue-specific promoter or a combination thereof, for the treatment of fibrotic disorders in various organs and a pharmaceutically acceptable carrier, and a method of treating fibrotic disorders, such as hepatic fibrosis, pulmonary fibrosis, renal fibrosis, keloids, hypertrophic scars, or combination thereof, in a patient by delivering a recombinant adenoviral vector expressing therapeutic proteins via an administration route to an organ. Claim 25 specifies the administration route is intravenous. Claims 28-30 and 32-34 specify the therapeutic protein for the treatment of fibrotic disorders is MMP-8, MMP-1, truncated receptor for TGF-beta type II, MMP-2, MMP-9 and MMP-13, respectively.

The specification discloses that the rat models, including healthy rats, rats intoxicated with carbon tetrachloride (CCl<sub>4</sub>) and rats with ligation of the bile duct (LCB), receive infusion of Ad5gal vector by iliac vein shows that the main target organ of the infused adenoviral vector is the liver. The spleen and the lung present a transduction grade lower than 1% and other organs, such as kidney, heart and brain, show no transduction at all (specification, pages 12-16).

The specification states “[t]he present invention relates to the creation of RECOMBINANT ADENOVIRAL vectors bearing exogenous genes that encodes for therapeutic proteins useful in the treatment of HEPATIC cirrhosis and generalized FIBROSIS, such as renal FIBROSIS, pulmonary FIBROSIS, HYPERTROPHIC scars and keloid of the skin, and/or in other target organs susceptible to suffer from it” and “the invention provides an effective way for the treatment of fibrosis through the employment of recombinant adenoviral vectors which are

claimed here, as well as the process to prepare these vectors, the pharmaceutical composition that contains them, and their therapeutic uses in the treatment of several fibrosis" (specification, page 1, first and second paragraphs). The "pharmaceutical composition" implies therapeutic use of said composition. Thus, the claims read on gene therapy for the treatment of various fibrotic diseases or disorders *in vivo*.

The claims encompass treating various fibrotic diseases or disorders in a patient by delivering a recombinant adenoviral vector expressing a therapeutic protein under the control of a promoter to various target organs via various administration routes *in vivo*. It is noted that claim 24 reads on using a recombinant adenoviral vector containing a therapeutic gene or DNA sequence of claim 22. Therefore, the claims encompass using **any therapeutic gene or the DNA sequence recited in claim 24**, i.e. MMP-1, MMP-2, MMP-8, MMP-9, MMP-13 and truncated receptor for TGF-beta type II. The specification fails to provide adequate guidance and evidence for delivering a recombinant adenoviral vector expressing any therapeutic protein under the control of a promoter via various administration routes *in vivo* such that sufficient therapeutic protein can be obtained so as to provide therapeutic effects in target organs for treating any fibrotic disease or disorder in a patient with the exception of the disclosed references cited in the amendment filed on 10-31-07, i.e. references Siller-Lopez et al., 2004 (Gastroenterology, Vol. 126, p. 1122-1133) and Garcia-Banuelos et al., 2002 (Gene Therapy, Vol. 9, p. 127-134).

The claims read on gene transfer and gene therapy *in vivo*. The nature of the invention being gene therapy, the state of the prior art was not well developed and was highly unpredictable at the time of filing. While progress has been made in recent years for gene transfer *in vivo*, vector targeting to desired tissues *in vivo* continues to be unpredictable and

inefficient as supported by numerous teachings available in the art. For example, Deonarain, M., 1998 (Expert Opin. Ther. Pat., Vol. 8, pages 53-69) indicates that one of the biggest problems hampering successful gene therapy is the "ability to target a gene to a significant population of cells and express it at adequate levels for a long enough period of time" (page 53, first paragraph). Verma et al., Sept. 1997 (Nature, Vol. 389, pages 239-242) reviews vectors known in the art for use in gene therapy and discusses problems associated with each type of vector. The teachings of Verma indicate a resolution to vector targeting has not been achieved in the art (see entire article). Verma also teaches appropriate regulatory elements may improve expression, but it is unpredictable what tissues such regulatory elements target (page 240, sentence bridging columns 2 and 3). Verma states that "The Achilles heel of gene therapy is gene delivery, and this is the aspect that we will concentrate on here. Thus far, the problem has been an inability to deliver genes efficiently and to obtain sustained expression...The use of viruses (viral vectors) is powerful technique, because many of them have evolved a specific machinery to deliver DNA to cells, However, humans have an immune system to fight off the virus, and our attempts to deliver genes in viral vectors have been confronted by these host responses." (e.g. p. 239, column 3). The adenoviral vector can induce both cell-killing "cellular" immune response and the antibody-producing "humoral" immune response from the host. The virally infected cells can be killed by cytotoxic T lymphocytes and the humoral response results in the generation of antibodies against adenoviral proteins. "There are considerable immunological problems to be overcome before adenoviral vectors can be used to deliver genes and produce sustained expression" (e.g. p. 241, left and middle column).

Eck et al., 1996 (Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 77-101) reports that numerous factors complicate *in vivo* gene therapy with respect to predictably achieving levels and duration of gene expression which have not been shown to be overcome by routine experimentation. These include, the fate of the DNA vector itself (volume of distribution, rate of clearance into the tissues, etc.), the *in vivo* consequences of altered gene expression and protein function, the fraction of vector taken up by the target cell population, the trafficking of the genetic material within cellular organelles, the rate of degradation of the DNA, the level of mRNA produced, the stability of the mRNA produced, the amount and stability of the protein produced, and the protein's compartmentalization within the cell, or its secretory fate, once produced. These factors differ dramatically based on the vector used, the protein being produced, and the disease being treated (e.g., bridging pages 81-82). In addition, Gorecki, 2001 (Expert Opin. Emerging Drugs, 6(2): 187-198) reports that "the choice of vectors and delivery routes depends on the nature of the target cells and the required levels and stability of expression" for gene therapy, and obstacles to gene therapy *in vivo* include "the development of effective clinical products" and "the low levels and stability of expression and immune responses to vectors and/or gene products" (e.g. abstract). Thus, administration route plays an important role in gene transfer efficiency.

Further, the administration route includes oral administration, intraperitoneal injection, topical administration, intravenous administration, intramuscular injection, and subcutaneous administration etc. As discussed above, the specification discloses that infusion of Ad5gal vector into rats by iliac vein shows that the main target organ of the infused adenoviral vector is the liver. Other organs, such as spleen, lung, kidney, heart and brain, show either very low

transduction efficiency or no transduction at all. It appears that when an adenoviral vector is administered via infusion or intravenous administration, most of the adenoviral vector reaches the liver but very little reaches other organs. The claims encompass treating fibrotic disorder or disease of various organs. The specification fails to provide adequate guidance and evidence for whether intravenous administration of an adenoviral vector to a patient could provide sufficient expression of a therapeutic protein in any organ other than the liver in said patient so as to provide therapeutic effect for treating various fibrotic disorders in different organs. The specification also fails to provide adequate guidance and evidence for whether various administration routes of an adenoviral vector to a patient could provide sufficient expression of a therapeutic protein in any organ, including the liver, in said patient so as to provide therapeutic effect for treating various fibrotic disorders in different organs. There is no evidence of record that shows administration of a recombinant adenoviral vector expressing a therapeutic protein under the control of a promoter, including different tissue-specific promoter, or a combination of promoters into a patient via various administration routes can provide therapeutic effects for treating various fibrotic disorders or diseases in said patient. In addition, Varga et al., 2007 (The Journal of Clinical Investigation, Vol. 117, No. 3, p. 557-567) points out that systemic sclerosis (SSc) is a prototypic multisystem fibrotic disorder and the fibrosis in SSc is not restricted to a single organ, and no therapy to date has been able to reverse or slow the progression of tissue fibrosis or substantially modify the natural progression of the disease (e.g. abstract). Therefore, one skilled in the art would not know how to use the recombinant adenoviral vector for treating various fibrotic diseases or disorders via various administration routes *in vivo*.

The claims also encompass using nucleotide sequences encoding various therapeutic proteins for treating various fibrotic diseases or disorders in a patient. However, different therapeutic proteins have different amino acid sequences and their biological functions would differ. The specification fails to provide adequate guidance and evidence for whether the claimed therapeutic protein or combination of therapeutic proteins would be able to treat various fibrotic diseases or disorders in different organs *in vivo*. It was known in the art that the amino acid sequence of a protein determines its structural and functional properties, and predictability of which amino acids can be removed from a protein's sequence and still result in similar activity is extremely complex, and well outside the realm of routine experimentation, because accurate predictions of a protein's structure from mere sequence data are limited. Rudinger, 1976 (Peptide Hormones, Edited by Parsons, University Park Press, Baltimore, p. 1-7), points out that "The significance of particular amino acids and sequences for different aspects of biological activity cannot be predicted *a priori* but must be determined from case to case by painstaking experimental study" (e.g. p. 6). Kaye et al., 1990 (Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 6922-6926) teaches that "A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding" (e.g. Title). Davis, C. G., 1990 (The New Biologist, Vol. 2, No. 5, p. 410-419) reports that EGF repeats appears in an extraordinarily diverse group of molecules, including growth factors, transmembrane molecules, extracellular matrix proteins, and soluble secreted proteins, and it is often difficult to deduce what contribution the EGF repeat makes in a totally unrelated protein (e.g. p. 410, left column). It appears that EGF repeat can contribute to different biological functions in different amino acid contexts, i.e. different proteins.

Further, Skolnick et al., 2000 (Trends in Biotech, Vol. 18, p. 34-39) states "Sequence-based methods for function prediction are inadequate because of the multifunctional nature of proteins. However, just knowing the structure of the protein is also insufficient for prediction of multiple functional sites. Structural descriptors for protein functional sites are crucial for unlocking the secrets in both the sequence and structural-genomics projects" (e.g. abstract). Skolnick further states that "Knowing a protein's structure does not necessarily tell you its function" and "Because proteins can have similar folds but different functions, determining the structure of a protein may or may not tell you something about its function" (e.g. p. 36, box 2). Therefore, biological function of a protein was unpredictable from mere amino acid sequence at the time of the invention and even same short stretch of amino acid sequence can show diverse biological functions while surrounded by different background amino acid sequences. There is no evidence of record that the claimed adenoviral vector expressing the recited therapeutic protein or combination of therapeutic proteins would be able to provide therapeutic effect *in vivo* so as to treat various fibrotic diseases or disorders in different organs. Therefore, one skilled in the art at the time of the invention would not know how to use the claimed adenoviral vector to treat various fibrotic diseases or disorders *in vivo*.

In view of the unpredictable nature of gene therapy *in vivo*, the limitation of using adenoviral vectors in gene delivery, and the unpredictable biological function of a protein from mere amino acid sequence, one skilled in the art at the time of the invention would not know how to use the recombinant adenoviral vector expressing any therapeutic protein for treating various fibrotic diseases or disorders via various administration routes *in vivo*. One skilled in the art would require to identify and characterize the nucleotide sequence of the therapeutic

protein, trial and error experimentation to determine the biological function of various therapeutic proteins, preparation of adenoviral vectors expressing various therapeutic proteins, administration of said viral vectors into a subject via various administration routes, trial and error experimentation to determine whether sufficient therapeutic protein is expressed at the target organ via various administration routes, and trial and error experimentation to determine whether the expressed therapeutic protein can provide therapeutic effect for treating various fibrotic diseases or disorders in vivo.

For the reasons discussed above, it would have required undue experimentation for one skilled in the art at the time of the invention to practice over the full scope of the invention claimed. This is particularly true given the nature of the invention, the state of the prior art, the breadth of the claims, the amount of experimentation necessary, the level of ordinary skill which is high, the working examples provided and scarcity of guidance in the specification, and the unpredictable nature of the art.

Applicants cite references Siller-Lopez (Exhibit A), Hernandez-Canaveral (Exhibit B), Gonzalez-Cuevas (Exhibit C), Miranda-Diaz (Exhibit D) and Garcia-Banuelos (Exhibit E) and argue that the rejection is overcome (amendment, p. 5-6). This is not found persuasive because of the reasons set forth above under 35 U.S.C. 112 first paragraph rejection. The in vitro data of Hernandez-Canaveral (Exhibit B) and Gonzalez-Cuevas (Exhibit C) cannot be extrapolated into in vivo success in gene therapy. Miranda-Diaz (Exhibit D) discusses the adenovirus-mediated delivery of human uPA which is irrelevant to the instant invention.

***Claim Rejections - 35 USC § 103***

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

7. Claims 22 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fernandez et al., 1998 (Surgery, Vol. 124, p. 129-136) in view of Hasty et al., 1990 (The Journal of Biological Chemistry, Vol. 265, No. 20, pp. 11421-11424).

Claims 22 and 28 are directed to a pharmaceutical composition comprising a therapeutically effective amount of unitary doses of  $1 \times 10^7$  pfu to  $1 \times 10^{14}$  pfu viral particles of recombinant adenoviral vectors containing a therapeutic gene or DNA sequence under the control of a ubiquitous promoter, a tissue-specific promoter or a combination thereof, that encodes one or more therapeutic proteins for the treatment of fibrotic disorders in various organs and a pharmaceutically acceptable carrier, wherein the therapeutic protein is MMP-8.

Fernandez teaches preparation of a recombinant adenovirus vector AdMMP-3 expressing MMP-3 protein under the control of CMV promoter and use of said adenovirus vector for ex vivo transfection of human saphenous vein grafting (hSVG) at a dose of  $1 \times 10^9$  pfu for studying modulation of MMP activity in hSVG (e.g. abstract, p. 130). Fernandez shows that adenovirus-mediated gene delivery is limited to the vessel's intima and strategy to infect medial smooth muscle cells need to be developed (e.g. abstract). The dose of  $1 \times 10^9$  pfu is in the range of  $1 \times 10^7$  pfu to  $1 \times 10^{14}$  pfu. The buffer solution containing the adenovirus vector is considered a pharmaceutically acceptable carrier. The term "pharmaceutical" does not carry weight in 35 U.S.C. 103(a) rejection.

Fernandez does not specifically teach the nucleotide sequence of MMP-8 gene.

Hasty teaches the cDNA sequence encoding the human neutrophil collagenase, i.e. MMP-8 (e.g. abstract, Figure 1).

It would have been *prima facie* obvious for one of ordinary skill in the art at the time of the invention to generate a composition comprising a recombinant adenoviral vector expressing a MMP-8 protein under the control of CMV promoter because Fernandez teaches preparation of an adenoviral vector containing the gene sequence of MMP-3 under the control of CMV promoter for studying modulation of MMP activity in hSVG, Hasty teaches the cDNA sequence encoding the human neutrophil collagenase (MMP-8), and MMP-8 is a member of MMP family.

One having ordinary skill in the art at the time the invention was made would have been motivated to do so in order to study modulation of MMP activity and expression of MMP in hSVG as taught by Fernandez with reasonable expectation of success.

8. Claims 22 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baker et al., 1996 (Matrix Biology, Vol. 15, pp. 383-395).

Claims 22 and 33 are directed to a pharmaceutical composition comprising a therapeutically effective amount of unitary doses of  $1 \times 10^7$  pfu to  $1 \times 10^{14}$  pfu viral particles of recombinant adenoviral vectors containing a therapeutic gene or DNA sequence under the control of a ubiquitous promoter, a tissue-specific promoter or a combination thereof, that encodes one or more therapeutic proteins for the treatment of fibrotic disorders in various organs and a pharmaceutically acceptable carrier, wherein the therapeutic protein is MMP-9.

Baker teaches preparation of an adenoviral vector containing the gene sequence of MMP-9 under the control of CMV promoter (abstract, p. 385). Baker further teaches that increased secretion of MMPs is implicated in many pathological conditions, including rheumatoid arthritis, restenosis and atherosclerosis etc. "Clear definition of the normal and pathological function of individual MMPs will benefit from approaches that use gene transfer to produce increases in MMP levels that mimic those observed in pathological conditions" (e.g. abstract).

Baker does not teach the dose of  $1 \times 10^7$  pfu to  $1 \times 10^{14}$  pfu.

It would have been *prima facie* obvious for one of ordinary skill in the art at the time of the invention to generate a recombinant adenoviral vector expressing a MMP-9 protein under the control of CMV promoter with dose of  $1 \times 10^7$  pfu to  $1 \times 10^{14}$  pfu because Baker teaches infecting cells with multiplicity of infection (MOI) of 0, 3, 30, 100, 300 or 1000 pfu/cell and determining effective dose is routine optimization of a result-effective variable and is obvious to one of ordinary skill.

One having ordinary skill in the art at the time the invention was made would have been motivated to do so in order to obtain effective dose to optimize the effect of the recombinant adenoviral vector with reasonable expectation of success.

***Conclusion***

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (571) 272-0726. The examiner can normally be reached on Monday to Friday from 9:30 am to 6 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for this group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

Application/Control Number:  
10/724,292  
Art Unit: 1632

Page 16

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Shin-Lin Chen, Ph.D.

A handwritten signature in black ink, appearing to read "Shin-Lin Chen".